Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Снижение частоты сердечных сокращений как терапевтическая цель: фокус на первичную профилактику

Полный текст:

Аннотация

В последнее время появились сообщения о наличии прямой связи частоты сердечных сокращений (ЧСС) с прогнозом в самых различных популяциях, включающих людей пожилого возраста, больных артериальной гипертонией, инфарктом миокарда, пациентов после стентирования коронарных артерий, лиц с избыточной массой тела и даже у молодых людей из группы низкого кардиоваскулярного риска. ЧСС стала рассматриваться в качестве еще одного независимого фактора риска (ФР) развития заболеваний сердечно-сосудистой системы. Однако, пока имеются подтверждения, что медикаментозное снижение ЧСС приводит к улучшению прогноза только у больных ишемической болезнью сердца и с хронической сердечной недостаточностью. В отношении пациентов без сердечно-сосудистых заболеваний ситуацию трактуют неоднозначно. В представленном обзоре обсуждаются возможности использования различных типов ритмурежающей терапии в рамках первичной профилактики.

Об авторах

Я. А. Орлова
НИИ кардиологии им. А.Л.Мясникова ФГБУ РКНПК
Россия

(контактное лицо) – заведующая консультативно-поликлиническим отделением

Тел.: (495) 414-69-70,
факс: (495) 414-66-12



Г. В. Макарова
Центральная поликлиника ФСБ РФ, Москва
Россия

начальник кардиологического отделения

Тел.: (495) 414-69-70,
факс: (495) 414-66-12



Г. В. Михайлов
НИИ кардиологии им. А.Л.Мясникова ФГБУ РКНПК
Россия

аспирант НДО

Тел.: (495) 414-69-70,
факс: (495) 414-66-12



Ф. Т. Агеев
НИИ кардиологии им. А.Л.Мясникова ФГБУ РКНПК
Россия

руководитель НДО

Тел.: (495) 414-69-70,
факс: (495) 414-66-12



Список литературы

1. DiFrancesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64(16): 1757-65.

2. Levine HJ. Rest heart rate and life expectancy. JACC 1997; 30: 1104-6.

3. Bramah N. Singh Morbidity and Mortality in Cardiovascular Disorders: Impact of Reduced Heart Rate. J Сardiovasc Pharmacol Therapeut 2001; 6(4): 313-31.

4. Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS Project. Am J Public Health 2001; 91:1258-63.

5. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-49.

6. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113(6): 1489-94.

7. Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J 2008; 29(22): 2772-81.

8. Шальнова С.А., Деев А.Д., Оганов Р.Г.и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.

9. Diaz A, Bourassa MG, Guertin MC, Tardif IC. Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.

10. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22(22): 2085-103.

11. Fox K, Ford I, Steg PG, et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in the patients with coronary artery disease and left-ventricular systolic disfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 817-21.

12. Chierchia S, Zingarelli A. Clinical interest of heart rate reduction in heart failure. Selective and Specific If inhibition in cardiovascular disease edited by Bramah N.Singh and Paul M.Vanhoutte. Lippincott Williams and Wilkins, 2003

13. Lechat P, Hulot JS, Escolano S, et al. CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-33.

14. Swedberg K, Komajda M, Bíhm M, et al, on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.

15. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 1999; 353: 2001-7.

16. Julius S. Corcoran lecture. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21: 886-93.

17. Corr PB, Gillis RA. Effect of autonomic neural influences on the cardiovascular changes induced by coronary occlusion. Am Heart J 1975; 89(6): 767-74.

18. Lujan HL, Palani G, Zhang L, DiCarlo SE. Targeted ablation of cardiac sympathetic neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats. Am J Physiol Heart Circ Physiol 2010; 298(5): H1330-9.

19. Nayate A, Moore SA, Weiss R, et al. Cardiac damage after lesions of the nucleus tractus solitarii. Am J Physiol Regul Integr Comp Physiol 2009; 296(2): R272-9.

20. Reduction in mortality after myocardial infarction with long-term betaadrenoceptor blockade. Multicentre international study: supplementary report. Br Med J 1977; 13;2(6084): 419-21.

21. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9.

22. Andersen SS, Hansen ML, Gislason GH, et al. Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction. Cardiology 2009; 112(2): 144-50.

23. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 20; 339(8): 489-97.

24. Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanisms of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987; 60: 738-46.

25. Di Francesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64: 16: 1757-65.

26. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.

27. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.

28. Kaplan PA, Manuck SB, Clarkson TB. The influence of heart rate on coronary artery atherosclerosis. J Cardiovasc Pharmacol 1987; 10: Suppl 2: S100-2.

29. Perski A, Hanstan A, Lindvall K, Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369-73.

30. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 606-9.

31. Kaplan PA, Manuck SB, Adams MR, et al. Propranolol inhibits coronary atherosclerosis in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987; 761: 1364-72.

32. Bonaa KH, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population. The Tromso Study. Circulation 1992; 86: 394-405.

33. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.

34. Laurent S, Boutouyrie P, Asmar R, et al. Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients Hypertension 2001; 37: 1236-41.

35. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-90.

36. Stefanadis C, Dernellis J,Tsiamis E, et al. Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J 2001; 22(2): 181.

37. Tomiyama H, Koij Y, Yambe M, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815-22.

38. Pynadath TI, Mukherjee DP. Dynamic mechanical properties of atherosclerotic aorta. A correlation between the cholesterol ester content and the viscoelastic properties of atherosclerotic aorta. Atherosclerosis 1977; 26(3): 311-8.

39. Farrar DJ, Bond MG, Sawyer JK, et al. Pulse wave velocity and morphological changes associated with early atherosclerosis progression in the aortas of cynomolgus monkeys. Cardiovasc Res 1984; 47(3): 425-32.

40. Miyai N, Arita M, Miyashita K, et al. The influence of obesity and metabolic risk variables on brachial-ankle pulse wave velocity in healthy adolescents. J of Hum Hypertension 2008; 12: 1-7.

41. Imanishi R, Seto S, Toda G, et al. High Brachial-Ankle Pulse Wave Velocity Is an Independent Predictor of the Presence of Coronary Artery Disease in Men. Hypertension Research 2004; 27(2): 71-8.

42. Milnor WR. Pulsative blood flow. New Engl J Med 1972; 287: 27-34.

43. Каро К., Педли Т., Шротер Р., Сид У. Механика кровообращения: Пер. с англ. Под ред. С.А. Регирера и В.М. Хаютина. Изд. “Мир”. Москва 1981.

44. Avolio AP, Deng FQ, Li WQ, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71: 202-10.

45. Cecelja M, Chowienczyk P. Dissociation of Aortic Pulse Wave Velocity With Risk Factors for Cardiovascular Disease Other Than Hypertension. Hypertension 2009; 54: 1328-36.

46. Benetos A, Adamopouls C, Bureau JM, et al. Determination of accelerated progression of arterial stiffness in normotensive subject and treated hypertensive subject over a 6-year period. Circulation 2002; 105: 1202-7.

47. Орлова Я.А., Макарова Г.В., Яровая Е.Б., Нуралиев Э.Ю., Агеев Ф.Т. Прогностическое значение различных параметров артериальной жесткости при ИБС. Сердце 2009; 2(46): 98-103.

48. Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation 2008; 117(18): 2377-87.

49. Kopeí G, Podolec P, Podolec J, et al. Atherosclerosis progression affects the relationship between endothelial function and aortic stiffness. Atherosclerosis 2008; 204: 250-4.

50. Jadhav UM, Kadam NN. Non-invasive assessment of arterial stiffness by pulse-wave velocity correlates with endothelial dysfunction. Indian Heart J 2005; 57(3): 226-32.

51. Poole-Wilson PA. ACE-inhibitors and calcium antagonists in patients after myocardial infarction. J Cardiovasc Pharmacology 1996; 28 (Suppl. 2): 25-30.

52. The Danish study group on verapamil in myocardial infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II – DAVIT-II). Am J Cardiol 1990; 66: 779-85.

53. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. for the INVEST Investigators. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290(21): 2805-16.

54. Gibson RS, Hansen JF, Messerli F, et al. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies Am J Cardiol 2000; 86: 275-9.

55. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29(10): 1327-34.

56. Murakami M, Ohba T, Xu F, et al. Modified sympathetic nerve system activity with overexpression of the voltage-dependent calcium channel beta3 subunit. J Biol Chem 2008; 283(36): 24554-60.

57. Tsuda K, Nishio I, Masuyama Y. Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension. Clin Exp Hypertens A 1989; 11 Suppl 1: 435-40.

58. Lefrandt JD, Heitmann J, Sevre K, et al. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. Blackwell Science Ltd Br J Clin Pharmacol 2001; 52: 687-92.

59. Di Francesco D. If inhibition: a novel mechanism of action. Eur Heart J 2003; 5(Suppl. G): 19-25.

60. Fox K, Ford I, Steg PG, et al. on behalf of the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebocontrolled trial. Lancet 2008; 372: 807-16.

61. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.

62. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 1999; 353: 2001-7.

63. van Veldhuisen DJ, Cohen-Solal A, Bíhm M, et al. SENIORS Investigator. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). JACC 2009; 53(23): 2150-8.

64. Tardif J-C Ford I, Tendera M, et al. for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529-36.

65. Gillman M, Kannel W, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148-54.

66. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-21.

67. Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346(11): 793-801.

68. Karvonen MJ. Physical activity in work and leisure time in relation to cardiovascular diseases. Ann Clin Res 1982;14 (Suppl 34): 118-23.

69. Hamer M, Ingle L, Carroll S, Stamatakis E. Physical Activity and Cardiovascular Mortality Risk: Possible Protective Mechanisms? Med Sci Sports Exerc 2011.

70. Short РМ, Lipworth S, Elder D, et al. Effect of β-blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549.

71. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-9.

72. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.

73. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004;44(3): 305-10.

74. Asmar R, London G, O’Rourke M, Safar ME. Improvement of blood pressure, arterial stiffness and wave reflections with a very low dose Perindopril/ Indapamide combination in hypertensive patients; a comparison with Atenolol. Hypertension. 2001; 38: 922-6.

75. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 2006; 113: 1213-25.

76. Kelly R, Daley J, Avolio A, O’Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989; 14(1): 14-21.

77. Polínia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit 2010; 15(5): 235-9.

78. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21: 663-7.

79. Fyhrquist F, Dahlof B, Devereux RB, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy Hypertension 2005; 45: 580-5.

80. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12.

81. Poulter N, Sever P. Anglo-Scandinavian Cardiac Outcomes Trial. History, results and implications for the management of high blood pressure. Birmingham: Sherborne Gibbs Ltd 2005.

82. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.

83. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 8(1): 35-44.

84. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 6 (Приложение 2).

85. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010.

86. Topouchian J, Asmar R, Sayegh F, et al. Changes in Arterial Structure and Function Under Trandolapril-Verapamil Combination in Hypertension. Stroke 1999; 30: 1056-64.

87. Boger-Megiddo I, Heckbert SR, Weiss NS, et al. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 2010; 25(340): 103.

88. Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension. JACC 2008; 52: 1482-9.

89. Bangalore S, Messerli FH, Ou F-S, et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010; 31(5): 552-60.

90. Manciaa G, Laurent S, Agabiti-Roseic E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.


Для цитирования:


Орлова Я.А., Макарова Г.В., Михайлов Г.В., Агеев Ф.Т. Снижение частоты сердечных сокращений как терапевтическая цель: фокус на первичную профилактику. Кардиоваскулярная терапия и профилактика. 2012;11(1):89-95.

For citation:


Orlova Y.A., Makarova G.V., Mikhailova G.V., Ageev F.T. Heart rate reduction as a therapeutic goal: focus on primary prevention. Cardiovascular Therapy and Prevention. 2012;11(1):89-95. (In Russ.)

Просмотров: 45


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)